Horgos Consulting Co., Ltd.

Main study objectives: 1. To evaluate the pharmacokinetic characteristics of ET-26-HCl and ET-26 after a single intravenous injection in healthy non-elderly/elderly subjects, and to provide guidance for the clinical application of ET-26-HCl. Secondary study objectives: 1. To evaluate the pharmacodynamics and safety of a single intravenous injection of ET-26-HCl in healthy non-elderly/elderly subjects; 2. To evaluate the pharmacokinetic characteristics of ET-26-HCl and etomidate acid after a single intravenous injection in healthy non-elderly/elderly subjects. Exploratory study objectives: 1. To explore the effect of CYP2C19 gene polymorphism on the pharmacokinetic parameters of ET-26 and etomidate acid.

Main study objectives: To evaluate the pharmacokinetic characteristics of methoxyetomidate hydrochloride for injection in subjects with mild hepatic impairment (Child-Pugh A), moderate hepatic impairment (Child-Pugh B) and normal liver function, and to provide a basis for the clinical application of methoxyetomidate hydrochloride in patients with liver impairment. Secondary study objectives: To evaluate the safety and pharmacodynamics of methoxyetomidate hydrochloride for injection in subjects with mild hepatic impairment (Child-Pugh A), moderate hepatic impairment (Child-Pugh B) and normal liver function. Exploratory study objectives: To explore and analyze the relationship between pharmacodynamic indicators (MOAA/S, BIS) and pharmacokinetic parameters of methoxyetomidate hydrochloride in subjects with different liver function status in this study. To analyze the genotype of CYP2C19 of the subjects in the study, and to explore the effect of genetic polymorphism on the pharmacokinetic parameters of methoxyetomidate hydrochloride based on the data of CYP2C19 genotype. To analyze the relationship between in vivo exposure to methoxyetomidate hydrochloride and liver damage.

Primary study objectives: 1. To evaluate the effect of rifampicin capsules/fluconazole capsules on the pharmacokinetics of ET-26-HCl injection in healthy subjects. 2. To evaluate the effect of ET-26-HCl injection on the pharmacokinetics of omeprazole enteric-coated capsules/midazolam injection in healthy subjects. Secondary study objectives: 1. To evaluate the effect of rifampicin capsules/fluconazole capsules on the pharmacodynamics and safety of ET-26-HCl injection in healthy subjects. 2. To evaluate the effect of ET-26-HCl injection on the safety of omeprazole enteric-coated capsules/midazolam injection in healthy subjects. Exploratory study objectives: 1. To explore the effect of CYP2C19 gene polymorphism on the pharmacokinetic parameters of ET-26, etomidate, omeprazole, and 5-hydroxyomeprazole.